论文部分内容阅读
目的:观察α干扰素治疗HBeAg(+)慢性乙型肝炎患者过程中病毒学及血清学动态变化情况,通过早期疗效预测终末疗效。方法:观察144例HBeAg(+)慢性乙型肝炎患者经α干扰素治疗24WK及随访24WK过程中HBV-DNA以及HBeAg变化情况。结果:经α干扰素治疗12、24、48WK时,HBV-DNA下降到可检测值以下病例数分别为32、32、31例;同期HBeAg发生血清转换病例数分别为16、17、21例。结论:干扰素治疗12WK时患者病毒学及血清学结果可早期预测终末疗效。
OBJECTIVE: To observe the virological and serological changes during the treatment of HBeAg (+) chronic hepatitis B patients with IFN-α, and to predict the final efficacy through early treatment. Methods: The changes of HBV-DNA and HBeAg in 144 HBeAg (+) chronic hepatitis B patients treated with interferon-alpha for 24 weeks and followed up for 24 weeks were observed. Results: After treated with interferon alfa for 12, 24 and 48 weeks, the number of HBV-DNA decreased to detectable value was 32, 32, and 31, respectively. The number of HBeAg-seroconversion cases was 16, 17 and 21 respectively during the same period. Conclusions: Virologic and serological results at 12 WK for interferon therapy predict early outcomes at an early stage.